Brief: Nabriva Therapeutics Says Received Delisting Determination Letter From Nasdaq
24/07/2023 14:26
July 24 (Reuters) - Nabriva Therapeutics PLC NBRV.O :
* NABRIVA THERAPEUTICS PLC SAYS ON JULY 21, CO RECEIVED
DELISTING
DETERMINATION LETTER FROM THE NASDAQ - SEC FILING
* NABRIVA THERAPEUTICS PLC SAYS CO DOES NOT PLAN TO APPEAL
NASDAQ’S DETERMINATION
Source text: [https://l1nq.com/StRpm]
Further company coverage: NBRV.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nabriva Therapeutics
See all newsBrief: Nabriva Therapeutics And Units Enter Asset Purchase Agreement With Sumitomo Pharma
Brief: Nabriva Therapeutics Says Received Delisting Determination Letter From Nasdaq
Brief: Nabriva Therapeutics Receives Notice Of Delisting Or Failure To Satisfy Continued Listing Rule From Nasdaq
Brief: Nabriva Therapeutics - On Jan 31, Co's Unit Entered Into Letter Agreement With 2 Units Of Merck & Co, About Distribution Agreement, Dated July 15, 2020
Brief: Nabriva Therapeutics Provides Corporate Update